A woman in O'Fallon sits at her kitchen table with a pharmacy receipt in one hand and her phone in the other. Her husband has been on his third antidepressant for two months. Someone at church mentioned a nasal spray treatment. Her first question is not whether it works. Her first question is whether their plan will pay for it.
If that sounds familiar, you are in good company. Across the 443 adults in our ten-state Midwest survey this summer, insurance kept turning out to be the hinge. This piece explains what that finding means, why coverage carries so much weight, and what you can do about it before you ever sit down with a doctor.
What the survey actually found
Respondents rated how heavily coverage would count in trying ketamine or esketamine for depression. It would decide the matter for 22 percent and weigh big for 43 percent, close to two in three combined at 65 percent. Some weight, 21 percent. None, only 14 percent. All of it comes from Pollfish's final, validated file.
Roughly one person in seven would decide without thinking about coverage. For everyone else, the plan card is part of the medical conversation.
Why coverage carries so much weight here
Part of the reason is simple arithmetic at the household level. A treatment for stubborn depression is rarely a single visit. Spravato, which is esketamine under a brand name, is approved for depression that earlier antidepressants did not adequately relieve, and it is sprayed in the nose at a certified clinic, with a two-hour-plus observation afterward. That means a series of visits over weeks, a very different financial question than one prescription.
Another part is trust. Coverage works as a quiet signal. When a plan pays for something, many people read that as a sign the treatment has cleared some bar of legitimacy. That instinct lines up with a separate result, where FDA approval carried heavy or deciding weight for 59 percent of respondents. Coverage and approval tend to travel together in people's minds.
Friction is not the same as a no
One of the most useful things the survey showed is that people will tolerate paperwork if coverage waits at the end of it. Offered an insured path with extra paperwork or a simpler self-pay path, 51 percent took the insured one, 23 percent would cover the bill themselves, and 26 percent were unsure.
If you are the one making calls for someone you love, remember that prior authorization and waiting do not mean no; the plan usually wants proof the treatment fits its approved use. For a walk-through of the billing pieces, read the Brain Recovery Centers explainer on what esketamine costs with and without insurance.
What "covered" can mean in practice
Coverage for a supervised treatment like esketamine is not one line item. Before you assume anything, it helps to know the pieces that may be billed separately:
- The medication itself, which may run through a pharmacy benefit or a medical benefit depending on your plan.
- The supervised visit and the monitoring time afterward.
- The evaluation that establishes whether you qualify in the first place.
- Any follow-up visits with the prescriber who manages your overall care.
A plan may treat these pieces differently, so ask about each by name.
A short list of calls worth making
If you live in O'Fallon or anywhere in St. Charles County, you can do most of the groundwork from your couch. Start by phoning your plan and asking:
- Does my plan cover esketamine (Spravato) for treatment-resistant depression, and is prior authorization required?
- Which certified locations near me are in network?
- Is the medication billed under my pharmacy benefit or my medical benefit?
- What documentation of past treatment does the plan usually want to see?
Note who you talked to and when. If a clinic later tells you something different, that note becomes useful.
If you are on Missouri Medicaid, called MO HealthNet, the same questions apply. In most cases a managed care company runs the benefit, and its name and number appear on the card. Call the plan, not just the state line, because the plan often makes the coverage decision.
Where your doctor fits in
Insurance may decide whether people try a treatment, but it does not replace the clinician who decides whether a treatment is right for you. In our poll, a physician's endorsement was the pull for 74 percent, far ahead of any ad, and 56 percent would begin with their primary doctor.
You bring the coverage questions; your doctor brings the medical judgment and the documentation insurers look for.
What this does not mean
None of this is a promise that esketamine is right for anyone in particular, or that it will be covered on a given plan. It is not approved for every kind of depression, and it is different from ketamine offered at home or in clinics outside the approved framework. A clinician familiar with your history decides what suits you.
If cost has kept you from asking, you are thinking like most people in this region. Asking about coverage early is the first step of care, not a detour.
If you or someone you love is in a dark place right now, the coverage questions can wait. Text or call 988 and a real person with the Suicide and Crisis Lifeline answers, free, at any hour in O'Fallon or elsewhere.
Methodology
We used Pollfish survey 395586438, which drew on its consumer panel until June 23, 2026, and closed with 443 completes. The O'Fallon-to-Omaha sample, all aged 18 to 64, spans Ohio, Minnesota, Missouri, Kansas, Wisconsin, Illinois, Indiana, Nebraska, Oklahoma and Iowa. Numbers are whole-sample percentages, now final. The publisher both ordered and funded it. It is market research on care decisions, not clinical evidence.